You are here:
Safe and effective human papillomarivus vaccines offer protection against 70% of all cervical cancer cases.
Gavi supports inactivated polio vaccine as part of routine immunisation programmes.
Gavi funds Japanese encephalitis catch-up campaigns. Countries then self-finance the vaccine for routine immunisation.
Gavi helps to combat measles through four types of vaccine support: measles second dose, measles-rubella, measles campaigns and outbreak responses.
The Gavi-funded measles-rubella vaccine provides a 2-in-1 shot against two devastating diseases.
Gavi-supported campaigns have reached more than 215 million people.
Gavi helps to prevent cholera outbreaks through its support to the global oral cholera vaccine stockpile.
With Gavi support, pentavalent vaccine is available in the 73 poorest countries in the world.
Gavi’s 2015 target of 45 pneumococcal introductions achieved more than one year ahead of schedule.
Gavi supports developing countries to introduce rotavirus vaccines, protecting against severe and deadly diarrhoea.
Gavi provides yellow fever support for routine immunisation, campaigns in high-risk countries and emergency stockpiles in case of outbreaks.
From 5 to 16 vaccine manufacturers supplying Gavi – from 1 to 10 based in emerging markets.
2001: 5 vaccine manufacturers - 1 based in an emerging market;
2014: 16 vaccine manufacturers– 10 based in emerging markets.
Concerned about the misuse of Gavi resources? Report it now.
© Gavi 2015
modal window here